Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

An antifungal acquisition
December 2019
SHARING OPTIONS:

HALIFAX, Nova Scotia—Appili Therapeutics Inc. expanded its pipeline last month with the acquisition of T-2307 (now known as ATI-2307) under an agreement with FUJIFILM Toyama Chemical Co. Ltd. Appili gains exclusive worldwide rights (ex-Japan) to develop and commercialize ATI-2305, and in return will make future regulatory and commercial milestone payments to FUJIFILM Toyama Chemical, as well as a royalty on any net sales. The compound is a novel, broad-spectrum antifungal agent that is not currently susceptible to existing resistance mechanisms. ATI-2307 has shown broad-spectrum activity in vitro and in vivo against fungi such as Cryptococcus and multi-drug-resistant Candida. Appili plans to focus initially on advancing the compound as a treatment for cryptococcal meningitis. So far, ATI-2307 has been evaluated in three Phase 1 clinical studies showing it to be well tolerated in humans at anticipated dose levels.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.